A real-world study of clofarabine and cytarabine combination therapy for patients with acute myeloid leukemia

Fiona C He, Smarika Sapkota, Sarah L Parker, Todd E De For, Erica D Warlick, Celalettin Ustun, Craig E Eckfeldt, Armin Rashidi, Andy Kurtzweil, Daniel J Weisdorf, Nelli Bejanyan

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Clofarabine and cytarabine (Clo + Ara-C) combinations have efficacy in treatment of acute myeloid leukemia (AML). We retrospectively analyzed clinical outcomes of 71 AML patients receiving Clo + Ara-C regimens at the University of Minnesota from 2011 to 2016: 44 patients (62%) had newly diagnosed AML and 27 patients (38%) had relapsed/refractory AML. The median age of patients was 69 years (interquartile range [IQR], 63–75 years). Nearly 60% of the patients had secondary AML, and about half of patients had adverse risk cytogenetics. Objective response rate (ORR) was 42% in all patients with complete remission (CR) rate of 20%. Progression-free survival (PFS) at 2 years was 16% (95% CI 8–27%) and overall survival (OS) at 2 years was 21% (95% CI 11–33%) for all patients. The 30-day mortality rate was 18%. Clo + Ara-C- containing regimens are an acceptable upfront therapy option for patients who are not candidates for “7 + 3” induction, but do not induce durable remissions.

Original languageEnglish (US)
Pages (from-to)2352-2359
Number of pages8
JournalLeukemia and Lymphoma
Volume59
Issue number10
DOIs
StatePublished - Oct 3 2018

Fingerprint

Cytarabine
Acute Myeloid Leukemia
Therapeutics
clofarabine
Cytogenetics
Disease-Free Survival
Survival
Mortality

Keywords

  • Ara-c
  • Clofarabine
  • acute myeloid leukemia
  • chemotherapeutic approaches
  • cytarabine
  • myeloid leukemias and dysplasias

PubMed: MeSH publication types

  • Journal Article

Cite this

A real-world study of clofarabine and cytarabine combination therapy for patients with acute myeloid leukemia. / He, Fiona C; Sapkota, Smarika; Parker, Sarah L; De For, Todd E; Warlick, Erica D; Ustun, Celalettin; Eckfeldt, Craig E; Rashidi, Armin; Kurtzweil, Andy; Weisdorf, Daniel J; Bejanyan, Nelli.

In: Leukemia and Lymphoma, Vol. 59, No. 10, 03.10.2018, p. 2352-2359.

Research output: Contribution to journalArticle

@article{bb5cde96257d44abb7d2e91a90960f6d,
title = "A real-world study of clofarabine and cytarabine combination therapy for patients with acute myeloid leukemia",
abstract = "Clofarabine and cytarabine (Clo + Ara-C) combinations have efficacy in treatment of acute myeloid leukemia (AML). We retrospectively analyzed clinical outcomes of 71 AML patients receiving Clo + Ara-C regimens at the University of Minnesota from 2011 to 2016: 44 patients (62{\%}) had newly diagnosed AML and 27 patients (38{\%}) had relapsed/refractory AML. The median age of patients was 69 years (interquartile range [IQR], 63–75 years). Nearly 60{\%} of the patients had secondary AML, and about half of patients had adverse risk cytogenetics. Objective response rate (ORR) was 42{\%} in all patients with complete remission (CR) rate of 20{\%}. Progression-free survival (PFS) at 2 years was 16{\%} (95{\%} CI 8–27{\%}) and overall survival (OS) at 2 years was 21{\%} (95{\%} CI 11–33{\%}) for all patients. The 30-day mortality rate was 18{\%}. Clo + Ara-C- containing regimens are an acceptable upfront therapy option for patients who are not candidates for “7 + 3” induction, but do not induce durable remissions.",
keywords = "Ara-c, Clofarabine, acute myeloid leukemia, chemotherapeutic approaches, cytarabine, myeloid leukemias and dysplasias",
author = "He, {Fiona C} and Smarika Sapkota and Parker, {Sarah L} and {De For}, {Todd E} and Warlick, {Erica D} and Celalettin Ustun and Eckfeldt, {Craig E} and Armin Rashidi and Andy Kurtzweil and Weisdorf, {Daniel J} and Nelli Bejanyan",
year = "2018",
month = "10",
day = "3",
doi = "10.1080/10428194.2018.1433297",
language = "English (US)",
volume = "59",
pages = "2352--2359",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",
number = "10",

}

TY - JOUR

T1 - A real-world study of clofarabine and cytarabine combination therapy for patients with acute myeloid leukemia

AU - He, Fiona C

AU - Sapkota, Smarika

AU - Parker, Sarah L

AU - De For, Todd E

AU - Warlick, Erica D

AU - Ustun, Celalettin

AU - Eckfeldt, Craig E

AU - Rashidi, Armin

AU - Kurtzweil, Andy

AU - Weisdorf, Daniel J

AU - Bejanyan, Nelli

PY - 2018/10/3

Y1 - 2018/10/3

N2 - Clofarabine and cytarabine (Clo + Ara-C) combinations have efficacy in treatment of acute myeloid leukemia (AML). We retrospectively analyzed clinical outcomes of 71 AML patients receiving Clo + Ara-C regimens at the University of Minnesota from 2011 to 2016: 44 patients (62%) had newly diagnosed AML and 27 patients (38%) had relapsed/refractory AML. The median age of patients was 69 years (interquartile range [IQR], 63–75 years). Nearly 60% of the patients had secondary AML, and about half of patients had adverse risk cytogenetics. Objective response rate (ORR) was 42% in all patients with complete remission (CR) rate of 20%. Progression-free survival (PFS) at 2 years was 16% (95% CI 8–27%) and overall survival (OS) at 2 years was 21% (95% CI 11–33%) for all patients. The 30-day mortality rate was 18%. Clo + Ara-C- containing regimens are an acceptable upfront therapy option for patients who are not candidates for “7 + 3” induction, but do not induce durable remissions.

AB - Clofarabine and cytarabine (Clo + Ara-C) combinations have efficacy in treatment of acute myeloid leukemia (AML). We retrospectively analyzed clinical outcomes of 71 AML patients receiving Clo + Ara-C regimens at the University of Minnesota from 2011 to 2016: 44 patients (62%) had newly diagnosed AML and 27 patients (38%) had relapsed/refractory AML. The median age of patients was 69 years (interquartile range [IQR], 63–75 years). Nearly 60% of the patients had secondary AML, and about half of patients had adverse risk cytogenetics. Objective response rate (ORR) was 42% in all patients with complete remission (CR) rate of 20%. Progression-free survival (PFS) at 2 years was 16% (95% CI 8–27%) and overall survival (OS) at 2 years was 21% (95% CI 11–33%) for all patients. The 30-day mortality rate was 18%. Clo + Ara-C- containing regimens are an acceptable upfront therapy option for patients who are not candidates for “7 + 3” induction, but do not induce durable remissions.

KW - Ara-c

KW - Clofarabine

KW - acute myeloid leukemia

KW - chemotherapeutic approaches

KW - cytarabine

KW - myeloid leukemias and dysplasias

UR - http://www.scopus.com/inward/record.url?scp=85041493093&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85041493093&partnerID=8YFLogxK

U2 - 10.1080/10428194.2018.1433297

DO - 10.1080/10428194.2018.1433297

M3 - Article

VL - 59

SP - 2352

EP - 2359

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 10

ER -